Moreover, these results provide a molecular explanation for the poor clinical outcomes observed in SSTR2high HCC patients, suggesting that SSTR2 expression is intricately linked with loss of cell adhesion, EMT activation, and tumor invasiveness, and may serve as a surrogate indicator of aggressive genomic alterations in liver cancer. The gene discussed is SSTR2; the disease is hepatocellular carcinoma.